<DOC>
	<DOCNO>NCT02627196</DOCNO>
	<brief_summary>The purpose trial develop valid scientific evidence safety effectiveness Baroreflex Activation Therapy® BAROSTIM NEO® System subject heart failure , define New York Heart Association ( NYHA ) functional class III leave ventricular ejection fraction ( LVEF ) ≤ 35 % despite treated appropriate heart failure guideline direct therapy , exclude subject eligible actively receive Cardiac Resynchronization Therapy ( CRT ) .</brief_summary>
	<brief_title>Barostim Therapy Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Currently NYHA Class II III heart failure . 2 . Left ventricular ejection fraction ≤ 35 % within 45 day prior randomization . 3 . Heart failure accompany BNP NTproBNP great equal predefined BNP/NTproBNP eligibility value within 45 day prior randomization . BNP/NTproBNP eligibility value adjust base subject 's Body Mass Index ( BMI ) , heart failure history , atrial fibrillation history . 4 . On optimal , stable , Guideline Directed Medical Therapy ( GDMT ) per country specific guideline treatment heartfailure throughout screening/baseline evaluation least 4 week prior obtain postconsent screen parameter . 5 . Sixminute hall walk ( 6MHW ) ≥ 150m AND ≤ 400m within 45 day prior randomization . 6 . The artery plan BAROSTIM implant must : At least one carotid bifurcation identification bilateral carotid duplex ultrasound within 6 month prior randomization : Below level mandible Has ulcerative carotid arterial plaque Has carotid atherosclerosis produce 50 % great reduction linear diameter internal carotid Has carotid atherosclerosis produce 50 % great reduction linear diameter distal common carotid No prior surgery , radiation , endovascular stent placement carotid artery carotid sinus region . 7 . If female childbearing potential , must use medically accept method birth control negative pregnancy test within 14 day randomization . 8 . Received standard cardiac work appropriate candidate study surgical procedure determine trial cardiologist trial surgeon . 9 . Subjects implanted cardiac rhythm management device utilize intracardiac lead , implanted neurostimulation device , must approve prior enrollment . 10 . Signed CVRxapproved informed consent form participation trial . 1 . Received cardiac resynchronization therapy ( CRT ) within 6 month randomization , actively receive CRT . 2 . Currently Class I indication cardiac resynchronization therapy ( CRT ) device accord American Heart Association/American College Cardiology/European Society Cardiology ( AHA/ACC/ESC ) guideline treatment congestive heart failure . 3 . Known suspected baroreflex failure autonomic neuropathy . 4 . AHA/ACC Stage D heart failure within 45 day prior randomization . 5 . BMI &gt; 40 . 6 . Serum estimate glomerular filtration rate ( eGFR ) &lt; 25 mL/min/173m^2 within 45 day prior randomization . 7 . Recurring rest heart rate either &lt; 60 beat per minute ( bpm ) &gt; 100 bpm via clinic measurement within 45 day prior randomization . ( Heart rate &lt; 60bpm applicable subject implant device capable pacing ) . 8 . Recurring symptomatic hypotension within 45 day prior randomization . 9 . Significant uncontrolled symptomatic bradyarrhythmias unstable ventricular arrhythmia . 10 . Subjects surgery occur , plan occur , within 45 day BAROSTIM NEO® implant procedure . 11 . Episode NYHA class IV heart failure acute pulmonary edema within 45 day prior randomization . 12 . Any follow within 3 month randomization : Myocardial infarction Unstable angina Percutaneous coronary intervention Cerebral vascular accident transient ischemic attack Sudden cardiac death 13 . Solid organ hematologic transplant , currently actively evaluate organ transplant . 14 . Has receive receiving leave ventricular assist device ( LVAD ) therapy . 15 . Has receive receive chronic dialysis . 16 . Heart failure secondary reversible cause , cardiac structural valvular disease , acute myocarditis pericardial constriction . 17 . Primary pulmonary hypertension . 18 . Infiltrative cardiomyopathy . 19 . Severe chronic obstructive pulmonary disease ( COPD ) severe restrictive lung disease . 20 . Active malignancy . 21 . Current plan treatment intravenous positive inotrope therapy 22 . Life expectancy less one year . 23 . Clinically significant psychological condition , physician 's opinion , would prohibit subject 's ability meet protocol requirement . 24 . Unable unwilling fulfill protocol medication compliance , test , followup requirement . 25 . Enrolled active another clinical trial ( unless previously approve CVRx Clinical Department ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>BAROSTIM NEO®</keyword>
	<keyword>Baroreceptor</keyword>
	<keyword>Baroreflex</keyword>
	<keyword>Baroreflex Activation Therapy™</keyword>
	<keyword>New York Heart Associate Class III Heart Failure</keyword>
</DOC>